Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca heart treatment ìhigh riskî

AstraZeneca's has revealed that its heart drug, AGI-1067, is a ìvery high-risk projectî, raising concerns over the British number two's current pipeline status

AstraZeneca's (AZ) has revealed that its heart drug, AGI-1067, is a ìvery high-risk projectî, raising concerns over the British number two's current pipeline status.

AGI-1067 is an anti-inflammatory atherosclerosis treatment for heart attacks and stroke. If successful, the molecule could achieve blockbuster status and bring in sales of billions of dollars a year.

AZ CEO, David Brennan admitted to the Times: ìWe have a low probability of success from our perspective. We believe there is a possibility that it could work, based on phase II data. It's the same reasons we went forward with NXY-059.î

After a number of late-stage drug failures, AZ has few treatments remaining. When the company admitted that NXY-059 did not work, its shares plummeted.

ìIf we get it, it will be significant. If we don't, we have three other products in our pipeline that we are moving along in phase II - two oncology products and a platelet inhibitor - and we are actively looking for others,î claimed Brennan.

AGI-1067 could reach the market in 2008, if phase III clinical trials show efficacy. City analysts are not so sure. While they believe the drug may generate peak sales of up to $5 billion (£2.6 billion) annually, they have adjusted their forecasts from $500 million (£254.8 million) to $1 billion (£509.6 million) to reflect the high risk of failure.

In 2005, AZ signed a $50 million licensing deal for the rights to AGI-167 with specialty US pharmaceutical company, Athero-Genics.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....
Looking back at the year when everything changed
COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families....

Infographics